Fuji Pharma Co., Ltd.
FY2026 September Quarter (Second Quarter) Financial Summary [Japanese Standards] (Consolidated)
For the second quarter of FY2026, net sales were 297.16 billion yen (up 23.3% YoY), and operating profit was 4.39 billion yen (up 90.8% YoY).
Key Figures
- Net Sales: 29,716 million yen (up 23.3% YoY)
- Operating Profit: 4,398 million yen (up 90.8% YoY)
- Net Income Attributable to Owners of Parent: 713 million yen (down 44.6% YoY)
AI要約
Performance Overview
In the second quarter of FY2026, consolidated net sales were 29,716 million yen (up 23.3% YoY), driven by the steady progress of new drugs in the women's healthcare field and biosimilar businesses. Operating profit was a significant 4,398 million yen (up 90.8% YoY), while net profit attributable to owners of the parent declined to 713 million yen (down 44.6% YoY) due to recording valuation losses on investment securities. Total assets reached 97,938 million yen, net assets increased to 51,363 million yen, and the equity ratio improved to 52.4%.
Dividend Status and Future Outlook
The annual dividend forecast for FY2026 is a total of 49 yen (an increase from the previous year), with a planned year-end dividend of 26 yen. The full-year earnings forecast remains unchanged from the plan announced on February 5, 2026, projecting net sales of 59,250 million yen (up 14.7% YoY), operating profit of 6,120 million yen (up 22.6% YoY), and net income attributable to owners of the parent of 2,240 million yen (down 25.3% YoY).
Net Sales Trend (million yen)
Operating Profit Trend (million yen)
Ordinary Income Trend (million yen)
Net Income Attributable to Owners of Parent (million yen)
Annual Dividends (Yen)
Fujii Pharmaceutical Industry Co., Ltd.
Company overview · Stock price · Financial data · All IR
